Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · BACIL PHARMA LTD. · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
Bacil Pharma Limited is classified under pharmaceuticals and biotechnology, but according to its audited FY26 results it currently has no revenue from operations. The full-year FY26 'total income from operations' of Rs 123.52 lakh (FY25: Rs 198.50 lakh) came entirely from other income, not from any product or service sales, and the statutory auditor flagged a complete revenue collapse and material uncertainty on the going-concern assumption. The only concrete business activity visible is the incorporation on 28 July 2026 of a wholly-owned subsidiary named Bacil Research and Development Private Limited, which is intended to carry out research and development work for the parent. Net profit after tax of Rs 155.55 lakh for FY26 was driven by a Rs 56.53 lakh deferred tax credit rather than operating earnings; profit before tax was actually a Rs 3.89 lakh loss. Total assets stood at Rs 2,739.26 lakh, with cash and cash equivalents down sharply from Rs 285.73 lakh to Rs 56.85 lakh and borrowings rising from Rs 16.39 lakh to Rs 1,639 lakh. The board has approved raising up to Rs 50 crore through a Rights Issue (with authorised share capital to rise by Rs 45 crore to Rs 65 crore) to fund what management describes as future operations. AR · MarketPing reader · 2026-08-02
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
₹ crore · standalone
FY22
FY23
FY24
FY25
FY26
Revenue
0
0
0
0
0
EBITDA (ex other income)
(4)
(0)
(0)
(0)
(0)
margin %
—
—
—
—
—
Owners' profit
(4)
(0)
(0)
0
2
EPS, as reported (₹)
(6.55)
(0.17)
(0.10)
0.64
1.11
ROE % · ROCE %
(315.2) · (315.3)
(9.3) · (9.3)
(4.9) · (4.9)
1.6 · 1.6
6.3 · 4.0
Debt / equity (x)
0.03
0.02
0.08
0.01
0.00
Cash from operations
(4)
(0)
(0)
0
2
Capex
0
0
0
0
0
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · BACIL PHARMA LTD. · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
₹ crore
Q2 FY25
Q3 FY25
Q4 FY25
Q1 FY26
Q2 FY26
Q3 FY26
Q4 FY26
Q1 FY27
Revenue
0
0
0
0
0
0
0
0
Profit before tax
0
(0)
0
1
0
0
0
0
Net profit
0
(0)
0
1
0
0
1
(0)
EPS (₹)
0.82
(0.10)
0.20
0.48
0.01
0.03
0.44
0.22
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
Company
M.cap ₹ cr
P/E
P/B
EV/EBITDA
ROE %
ROCE %
Rev CAGR 5y %
EBITDA m. %
SUN PHARMACEUTICAL IND L
4,22,229
34.9
5.03
22.6
13.7
17.5
11.8
32.3
DIVI S LABORATORIES LTD
2,48,067
84.9
14.80
64.0
15.3
18.8
8.7
42.8
TORRENT PHARMACEUTICALS L
1,56,270
73.8
8.89
38.8
12.2
8.0
11.8
33.1
ZYDUS LIFESCIENCES LTD
1,10,978
24.8
3.75
14.4
17.3
18.0
12.4
25.2
LAURUS LABS LIMITED
1,07,937
98.6
19.87
60.1
16.4
17.2
7.2
32.0
CIPLA LTD
1,05,570
31.3
3.06
16.1
11.2
14.7
8.0
19.7
DR. REDDY S LABORATORIES
98,530
30.5
2.58
13.2
10.9
13.0
12.1
15.0
MANKIND PHARMA LIMITED
98,294
48.1
5.94
27.1
11.7
10.8
—
27.3
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
Metric
Company
Group median
Rank
Better than
P/E (TTM)
34.6
31.2
88 of 158
45%
P/B
1.4
3.1
33 of 163
80%
ROCE
4.0
10.8
136 of 183
26%
ROE
6.3
9.8
110 of 166
34%
Debt / Equity
0.0
0.2
1 of 166
79%
Profit growth
(102.9)
30.9
146 of 158
8%
Market cap
34
857
157 of 181
13%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · BACIL PHARMA LTD. · 9 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
1-day %
5-day %
8 Oct 2026 · Company Secretary resigns effective October 8, 2026
management changes
medium
—
—
5 Oct 2026 · Board meeting on 14 Oct 2026 to consider Q2 FY27 results
results
low
—
—
26 Sept 2026 · Trading window closed from Oct 1 for Q2 results
compliance
minimal
—
—
23 Sept 2026 · Bacil Pharma 39th AGM held - key resolutions tabled including MD elevation and capital hike
board shareholder meetings
low
—
—
31 Aug 2026 · Bacil Pharma submits FY26 annual report, 39th AGM on Sep 23 via VC
results
medium
—
—
29 Aug 2026 · Bacil Pharma 39th AGM on Sep 23; capital hike and MD appointment
board shareholder meetings
low
—
—
29 Aug 2026 · Book Closure from Sept 17 to 23 for 39th Annual General Meeting
board shareholder meetings
low
—
—
29 Aug 2026 · Board approves 39th AGM notice and capital hike from Rs 20 cr to Rs 70 cr
board shareholder meetings
low
—
—
25 Aug 2026 · Bacil Pharma appoints two new directors to strengthen its Board
management changes
medium
—
—
25 Aug 2026 · Board appoints two new directors - one Independent, one Non-Executive
management changes
medium
—
—
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
